PatientID: HDR07

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
PLR: Potential Low-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance
S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	**S**	
	DRV	**S**	
	FPV	**S**	
	IDV	**S**	
	LPV	**S**	
	NFV	**S**	
	SQV	**S**	
	TPV	**S**	
NRTI	ABC	**LR**	D67N;K70R;K219Q
	AZT	**HR**	
	D4T	**IR**	
	DDI	**IR**	
	FTC	**PLR**	
	LMV	**PLR**	
	TDF	**LR**	
NNRTI	DOR	**IR**	P225H;K103N;E138A
	EFV	**HR**	
	ETR	**PLR**	
	NVP	**HR**	
	RPV	**LR**	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
PI	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
NRTI	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
NNRTI	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
INSTI	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
NRTI	D67N is a non-polymorphic TAM associated with low-level resistance to AZT.
	K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs.
	K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs.
NNRTI	E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal.
	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
	P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.
INSTI	